| 1. |
Payen JF, Dupuis C, Trouve-Buisson T, et al. Corticosteroid after etomidate in critically ill patients: a randomized controlled trial[J]. Crit Care Med, 2012, 40(1): 29-35.
|
| 2. |
Ray DC, McKeown DW. Etomidate for critically ill patients. Pro: yes we can use it[J]. Eur J Anaesthesiol, 2012, 29(11): 506-510.
|
| 3. |
Chan CM, Mitchell AL, Shorr AF. Etomidate is associated with mortality and adrenal insufficiency in sepsis: a meta-analysis[J]. Crit Care Med, 2012, 40(11): 2945-2953.
|
| 4. |
Sterling SA, Puskarich MA, Jones AE. The effect of etomidate on mortality in sepsis remains unclear[J]. Crit Care Med, 2013, 41(6): e95.
|
| 5. |
Sunshine JE, Deem S, Weiss NS, et al. Etomidate, adrenal function, and mortality in critically ill patients[J]. Respir Care, 2013, 58(4): 639-646.
|
| 6. |
Morgan M, Lumley J, Whitwam JG. Etomidate, a new water-soluble non-barbiturate intravenous induction agent[J]. Lancet, 1975, 1(7913): 955-956.
|
| 7. |
Ledingham IM, Watt I. Influence of sedation on mortality in critically ill multiple trauma patients[J]. Lancet, 1983, 1(8336): 1270.
|
| 8. |
Flynn G, Shehabi Y. Pro/con debate: is etomidate safe in hemodynamically unstable critically ill patients[J]. Crit Care, 2012, 16(4): 227.
|
| 9. |
Cherfan AJ, Arabi YM, Al-Dorzi HM, et al. Advantages and disadvantages of etomidate use for intubation of patients with sepsis[J]. Pharmacotherapy, 2012, 32(5): 475-482.
|
| 10. |
Forman SA. Clinical and molecular pharmacology of etomidate[J]. Anesthesiology, 2011, 114(3): 695-707.
|
| 11. |
Pearl RG. ACP Journal Club. Review: etomidate increased mortality and adrenal insufficiency in adults with sepsis[J]. Ann Intern Med, 2013, 158(4): JC10.
|
| 12. |
Albert SG, Ariyan S, Rather A. The effect of etomidate on adrenal function in critical illness: a systematic review[J]. Intensive Care Med, 2011, 37(6): 901-910.
|
| 13. |
Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock[J]. N Engl J Med, 2008, 358(2): 111-124.
|
| 14. |
Cuthbertson BH, Sprung CL, Annane D, et al. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock[J]. Intensive Care Med, 2009, 35(11): 1868-1876.
|
| 15. |
Jung B, Clavieras N, Nougaret S, et al. Effects of etomidate on complications related to intubation and on mortality in septic shock patients treated with hydrocortisone: a propensity score analysis[J]. Crit Care, 2012, 16(6): R224.
|
| 16. |
Griesdale DE. Etomidate for intubation of patients who have sepsis or septic shock--where do we go from here[J]. Crit Care, 2012, 16(6): 189.
|
| 17. |
Ehrman R, Wira C, Lomax A, et al. Etomidate use in severe sepsis and septic shock patients does not contribute to mortality[J]. Internal and Emergency Medicine, 2011, 6(3): 253-257.
|
| 18. |
Cotten JF, Husain SS, Forman SA, et al. Methoxycarbonyletomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression[J]. Anesthesiology, 2009, 111(2): 240-249.
|
| 19. |
Cotten JF, Le GR, Banacos N, et al. Closed-loop continuous infusions of etomidate and etomidate analogs in rats: a comparative study of dosing and the impact on adrenocortical function[J]. Anesthesiology, 2011, 115(4): 764-773.
|
| 20. |
Pejo E, Ge R, Banacos N, et al. Electroencephalographic recovery, hypnotic emergence, and the effects of metabolite after continuous infusions of a rapidly metabolized etomidate analog in rats[J]. Anesthesiology, 2012, 116(5): 1057-1065.
|
| 21. |
Husain SS, Pejo E, Ge R, et al. Modifying methoxycarbonyl etomidate inter-ester spacer optimizes in vitro metabolic stability and in vitro hypnotic potency and duration of action[J]. Anesthesiology, 2012, 117(5): 1027-136.
|
| 22. |
Ge R, Pejo E, Gallin H, et al. The pharmacology of cyclopropylmethoxycarbonyl metomidate: a comparison with propofol[J]. Anesth Analg, 2014, 118(3): 563-567.
|
| 23. |
Campagna JA, Pojasek K, Grayzel D, et al. Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs[J]. Anesthesiology, 2014, 121(6): 1203-1216.
|
| 24. |
Ge R, Pejo E, Cotten JF, et al. Adrenocortical suppression and recovery after continuous hypnotic infusion: etomidate versus its soft analogue cyclopropyl-methoxycarbonyl metomidate[J]. Crit Care, 2013, 17(1): R20.
|
| 25. |
Ge R, Pejo E, Husain SS, et al. Electroencephalographic and hypnotic recoveries after brief and prolonged infusions of etomidate and optimized soft etomidate analogs[J]. Anesthesiology, 2012, 117(5): 1037-1043.
|
| 26. |
Cotten JF, Forman SA, Laha JK, et al. Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function[J]. Anesthesiology, 2010, 112(3): 637-44.
|
| 27. |
Roumen L, Sanders MP, Pieterse K, et al. Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics[J]. J Comput Aided Mol Des, 2007, 21(8): 455-471.
|
| 28. |
Pejo E, Feng Y, Chao W, et al. Differential effects of etomidate and its pyrrole analogue carboetomidate on the adrenocortical and cytokine responses to endotoxemia[J]. Crit Care Med, 2012, 40(1): 187-192.
|
| 29. |
Desai R, Miller KW, Raines DE. The pyrrole etomidate analog carboetomidate potently inhibits human 5-HT3A receptor function: comparisons with etomidate and potential implications for emetogenesis[J]. Anesth Analg, 2013, 116(3): 573-579.
|
| 30. |
Pejo E, Cotten JF, Kelly EW, et al. In vivo and in vitro pharmacological studies of methoxycarbonyl-carboetomidate[J]. Anesth Analg, 2012, 115(2): 297-304.
|
| 31. |
Pejo E, Santer P, Jeffrey S, et al. Analogues of etomidate: modifications around etomidate’s chiral carbon and the impact on in vitro and in vitro pharmacology[J]. Anesthesiology, 2014, 121(2): 290-301.
|
